BPC-157 Dosage in the Research Literature

BPC-157 dosage in rodent studies spans a remarkably wide range depending on model and route. Tissue-repair and healing studies most commonly use 10 μg/kg/day intraperitoneally. Ultra-low-dose studies confirm efficacy at 10 ng/kg.^[5][8] The literature documents efficacy across a wide range, suggesting a flat or plateau dose-response curve rather than a strict threshold effect in rodent models.

The BPC-157 dosage in research literature does not establish a human clinical dose. No dose-ranging study in humans has been published. The three published human pilot studies did not report a standardized dose schedule.^[21]

TB-500 dose ranges in wound healing models span 0.5–10 mg/kg.^[22] No TB-500-fragment-specific human pharmacokinetic study has been published.

The BPC-157 TB-500 blend dosage most commonly referenced in research-community literature uses equal proportioning of the two components: 5 mg:5 mg or 10 mg:10 mg per vial.^[22] These formulations are conventions built on individual compound dose ranges, not controlled combination trials. BPC-157 rodent studies use 10 μg/kg (IP) as the primary tissue-repair dose; TB-500 rodent wound healing studies use 0.5–10 mg/kg — a much wider range reflecting variation across wound models and species.^[4][22] The orders-of-magnitude difference in individual-compound rodent dose ranges means that designing a rationally grounded 1:1 blend is not straightforward from the literature alone; the 5:5 convention is a practical research-community compromise, not an evidence-based fixed ratio.

BPC-157 pharmacokinetics in rats show an intravenous elimination half-life of approximately 15.2 minutes and intramuscular bioavailability of 14–19%. In beagle dogs, IV half-life is approximately 5.27 minutes with IM bioavailability of 45–51%.^[7] The compound is excreted primarily via urine and bile with linear pharmacokinetic characteristics.

BPC-157 is stable in gastric juice for more than 24 hours — a property that provides the mechanistic basis for the observed oral-route systemic effects in rodent studies.^[7] In oral drinking-water models (10 μg/kg in 12 mL per rat per day), BPC-157 demonstrated anti-ulcer, mucosal healing, and cytoprotective activity consistent with systemic absorption.^[22]

BPC-157 has been studied via: intraperitoneal injection, subcutaneous injection, intramuscular injection, intravenous injection, oral gavage, oral drinking water, and topical cream application.^{[4][7][8][22]} Consistent healing effects were documented via all three primary routes (intraperitoneal, topical, oral) in the medial collateral ligament study over a 90-day period^[8] — a notable finding suggesting the compound is active regardless of route in rodent tissue-repair models. TB-500 has been studied topically, intraperitoneally, and subcutaneously.^[10][11] GHK-Cu has been studied topically, intradermally, systemically in animal models, and in liposomal topical formulations.^[14][17]

Rodent studies typically administer BPC-157 once daily subcutaneously or intraperitoneally — the Krivic 2006 tendon model used daily IP injection over the study period;^[4] the Cerovecki 2010 ligament study used daily IP and oral administration over 90 days.^[8] TB-500 administration in studies ranges from daily to twice-weekly depending on the injury model and observation period. No consensus human protocol exists in the peer-reviewed literature for either compound, individually or in combination.

Research-grade peptide vials are lyophilized (freeze-dried) for stability. Published research protocols describe reconstitution with bacteriostatic water (0.9% benzyl alcohol saline) at concentrations of 1–2 mg/mL.^[24] GHK-Cu solution exhibits a characteristic blue-green color upon reconstitution due to copper(II) chelation — an expected chemical property of copper(II) complexes, not an indicator of degradation.^[24] Lyophilized peptide blends are typically stored at −20°C long-term and 2–8°C after reconstitution. BPC-157 and TB-500 rodent studies most commonly use subcutaneous or intraperitoneal injection routes.

In rat tendon and muscle models, measurable tissue changes with BPC-157 appear within 7–14 days of dosing — the Krivic 2006 tendon study documented improved AFI scores and biomechanical properties; the Cerovecki 2010 ligament study showed improvements at multiple time-points across 90 days.^[4][8] Thymosin beta-4 wound healing studies in rats show reepithelialization changes within 4–7 days.^[10] GHK-Cu liposomal wound healing shortened time to closure to 14 days in the mouse scald model.^[17] No validated human timeline exists.

GHK-Cu is active in fibroblast culture at 10⁻¹² to 10⁻⁹ M — concentrations in the picomolar-to-nanomolar range.^[16] Plasma endogenous GHK levels are approximately 200 ng/mL at age 20 and approximately 80 ng/mL by age 60 — providing a natural reference point for the molecule's physiological concentration range.^[14] No injectable synthetic GHK-Cu pharmacokinetic study has been identified in the published literature; topical formulation strategies (palmitoylation, copper complexation, liposomal encapsulation) are the primary delivery research focus.^[26]